S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

被引：0
|
作者：
Patel, Sapna Pradyuman
Othus, Megan
Moon, James
Tetzlaff, Michael T.
Buchbinder, Elizabeth Iannotti
Sondak, Vernon K.
Lowe, Michael C.
Campos, Danae
Sharon, Elad
Korde, Larissa A.
Carson, William Edgar
Ribas, Antoni
Grossmann, Kenneth F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Southwest Oncol Grp, Stat Ctr, Seattle, WA USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Emory Univ, Dept Surg, Atlanta, GA USA
[7] SWOG Operatons Off, San Antonio, TX USA
[8] NCI, Bethesda, MD 20892 USA
[9] NCI, Clin Invest Branch, Bethesda, MD 20892 USA
[10] Ohio State Univ, Dept Surg, Comprehens Canc Ctr, Columbus, OH 43210 USA
[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10090
引用
收藏
页数：2
相关论文
共 50 条
  • [1] S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.
    Patel, Sapna Pradyuman
    Othus, Megan
    Moon, James
    Tetzlaff, Michael
    Buchbinder, Elizabeth Iannotti
    Sondak, Vernon K.
    Lowe, Michael C.
    Mireles, Catrina
    Sharon, Elad
    Korde, Larissa A.
    Guild, Samantha
    Carson, William Edgar
    Ribas, Antoni
    Grossmann, Kenneth F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial.
    Olivier, Timothee
    Prasad, Vinay
    [J]. TRANSLATIONAL ONCOLOGY, 2024, 45
  • [3] Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
    Patel, S.
    Othus, M.
    Wright, P.
    Hyngstrom, J.
    Lao, C. D.
    Truong, T-G.
    Chandra, S.
    Kendra, K.
    Devoe, C.
    Hegde, A.
    Mangla, A.
    Lowe, M.
    Buchbinder, E.
    Kirkwood, J. M.
    Sharon, E.
    Korde, L.
    Moon, J.
    Sondak, V. K.
    Ribas, A.
    Prieto, V.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1288 - S1288
  • [4] Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
    Patel, S.
    Othus, M.
    Prieto, V.
    Lowe, M.
    Buchbinder, E.
    Chen, Y.
    Hyngstrom, J.
    Lao, C. D.
    Truong, T-G.
    Chandra, S.
    Kendra, K.
    Devoe, C.
    Hedge, A.
    Mangla, A.
    Sharon, E.
    Korde, L.
    Moon, J.
    Sondak, V.
    Ribas, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1408 - S1408
  • [5] NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
    Mao, Lili
    Si, Lu
    Dai, Jie
    Bai, Xue
    Li, Caili
    Wei, Xiaoting
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Tang, Bixia
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Zhou, Li
    Kong, Yan
    Wu, Xiaowen
    Li, Siming
    Li, Juan
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [7] Surgical Outcomes of SWOG1801: Neoadjuvant/adjuvant Versus Adjuvant Pembrolizumab for Resectable Stage III-IV Melanoma
    Lowe, Michael C.
    Hyngstrom, John R.
    Wright, Gerald P.
    Othus, Megan
    Sharon, Elad
    Kirkwood, John M.
    Ribas, Antoni
    Patel, Sapna P.
    Sondak, Vernon K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S49 - S49
  • [8] Immunological results of a phase II randomized trial of multipeptide vaccines for melanoma.
    Slingluff, CL
    Petroni, G
    Bullock, KA
    Bissonnette, E
    Hibbitts, S
    Murphy, C
    Anderson, N
    Grosh, WW
    Neese, PY
    Fink, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 710S - 710S
  • [9] SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Tarhini, Ahmad A.
    Patel, Sapna Pradyuman
    Moon, James
    Sondak, Vernon K.
    Kirkwood, John M.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Adjuvant chemotherapy versus biochemotherapy for stage II malignant melanoma. A phase II/III study
    Andreadis, Charalampos
    Boutis, Anastasios
    Michou, Dimitra
    Oikonomou, Spiros
    Vachtsevanos, Kostas
    Mouratidou, Despina
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 202 - 203
12345